Management of Constipation in Older Adults

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2015 Sep 15;92(6):500-504.

  Patient information: A handout on constipation, written by the authors of this article.

Author disclosure: No relevant financial affiliations.

Chronic constipation is common in adults older than 60 years, and symptoms occur in up to 50% of nursing home residents. Primary constipation is also referred to as functional constipation. Secondary constipation is associated with chronic disease processes, medication use, and psychosocial issues. Fecal impaction should be treated with mineral oil or warm water enemas. Most patients are initially treated with lifestyle modifications, such as scheduled toileting after meals, increased fluid intake, and increased dietary fiber intake. Additional fiber intake in the form of polycarbophil, methylcellulose, or psyllium may improve symptoms. Fiber intake should be slowly increased over several weeks to decrease adverse effects. The next step in the treatment of constipation is the use of an osmotic laxative, such as polyethylene glycol, followed by a stool softener, such as docusate sodium, and then stimulant laxatives. Long-term use of magnesium-based laxatives should be avoided because of potential toxicity. If symptoms do not improve, a trial of linaclotide or lubiprostone may be appropriate, or the patient may be referred for further diagnostic evaluation. Peripherally acting mu-opioid antagonists are effective for opioid-induced constipation but are expensive.

Chronic constipation occurs in 16% of adults, with older patients experiencing constipation more often.1 About one-third of adults 60 years or older report at least occasional constipation1, and in nursing home residents, the prevalence is 50% or more.2 Approximately 33 million adults in the United States have constipation resulting in 2.5 million physician visits and 92,000 hospitalizations each year.3

View/Print Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Increased exercise does not improve symptoms of constipation in nursing home residents or older adults.

A

810

Polyethylene glycol (Miralax) is preferred over lactulose for the treatment of constipation because it is more effective and has fewer adverse effects.

A

29

Linaclotide (Linzess) and lubiprostone (Amitiza) are more effective than placebo for chronic constipation.

B

24, 31

Peripherally acting mu-opioid antagonists are more effective than placebo for chronic opioid-induced constipation.

B

23, 34


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Increased exercise does not improve symptoms of constipation in nursing home residents or older adults.

A

810

Polyethylene glycol (Miralax) is preferred over lactulose for the treatment of constipation because it is more effective and has fewer adverse effects.

A

29

Linaclotide (Linzess) and lubiprostone (Amitiza) are more effective than placebo for chronic constipation.

B

24, 31

Peripherally acting mu-opioid antagonists are more effective than placebo for chronic opioid-induced constipation.

B

23, 34


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Definitions

Constipation is a clinical diagnosis based on symptoms of incomplete elimination of stool, difficulty passing stool, or both. Patients typically experience other symptoms such as hard stools, abdominal bloating, pain, and distention. Constipation may be present with normal stool frequency, defined as at least one stool three times per week, or with daily bowel movements.1 Chronic constipation is characterized by the presence of symptoms for at least three months out of the preceding 12 months.

PRIMARY CONSTIPATION

Primary constipation, or functional constipation, is classified into three subtypes: normal transit constipation, slow transit constipation, and disorders of defecation. Often, more than one subtype occurs simultaneously.4 Normal transit constipation is the most common. Patients report hard stool or difficulty with defecation, but have normal stool frequency.4 Slow transit constipation, caused by abnormal innervation of the bowel or visceral myopathy, leads to increased transit time of stool through the colon with infrequent defecation, bloating, and abdominal discomfort.5 Disorders of defecation can occur in any age group but are particularly common in older patients.6 Defecation may be impaired by decreased smooth muscle contraction in the rectum or the inability to relax the muscles of defecation. In older adults, rectal receptors may have a diminished response to stretching, blunting the urge to defecate despite accumulation of large quantities of stool.

SECONDARY CONSTIPATION

Causes of secondary constipation include medication use, chronic disease processes, and psychosocial issues. A previous article in American Family Physician reviewed the diagnostic approach to chronic constipation in older adults (http://www.aafp.org/afp/2011/0801/p299.html).

Initial Management

Clinicians should discuss goals of treatment with patients and caregivers. The primary goal should be symptom improvement, and the secondary goal should be the passage of soft, formed stool without straining at least three times per week.4 Initially, any fecal impaction should be treated with enemas or manual disimpaction. Fecal impaction is suggested by a history of constipation with overflow diarrhea, and is confirmed by rectal examination with a plain abdominal radiograph, if needed.

Nonpharmacologic Interventions

BEHAVIORAL INTERVENTIONS

To take advantage of the gastrocolic reflex, patients should schedule toileting after meals.4 They should place their feet on a small step stool instead of on the floor to straighten the anorectal junction. Patients in long-term care facilities should be allowed adequate time and privacy for bowel movements, and should avoid using bedpans to defecate.7

Exercise programs do not improve symptoms of constipation in nursing home residents and older adults810; however, lifestyle education, including exercise and advice on increasing fluid and fiber intake, decreased constipation in one small study.11

There are no randomized controlled trials (RCTs) evaluating the benefit of water supplementation alone to treat constipation, although water supplementation totaling 1.5 to 2 L per day improved stool frequency in middle-aged adults on a high-fiber diet.12

The recommended daily fiber intake is 20 to 35 g per day. Intake should be slowly increased over several weeks to decrease adverse effects, including flatulence, abdominal cramping, and bloating.13

BIOFEEDBACK

Biofeedback to retrain the defecation muscles may be effective for treating constipation caused by pelvic floor dysfunction. With this technique, anorectal electromyography or a manometry catheter is used to give patients feedback when evacuating a rectal balloon. One systematic review concluded that there is insufficient evidence from high-quality trials to support the effectiveness of biofeedback.14 Since the publication of this review, a randomized trial of 88 persons with obstructive constipation found that biofeedback-guided pelvic floor exercises were superior to polyethylene glycol (PEG; Miralax) in improving constipation symptoms at six-month follow-up.15 Biofeedback may be appropriate for patients who are physically and mentally capable of participating.

Pharmacologic Treatment

Most older adults with chronic constipation eventually require a laxative to alleviate symptoms. A systematic review of laxative treatment in older persons showed varying degrees of effectiveness and concluded that therapy should be individualized.16  There are limited data on long-term use of medications for constipation in older persons. Medications for constipation are listed in Table 1.1624 Figure 1 provides a suggested approach to the management of chronic constipation in older adults. In patients with a poor response to behavioral interventions and laxatives, referral may be warranted for assessment of colonic transit times and for rectal manometry to evaluate for disorders of defecation.

View/Print Table

Table 1.

Medications for the Treatment of Constipation

AgentTypical dosage*Time of onsetAdverse effects

Bulking agents

Methylcellulose powder

19 g per day

12 to 72 hours

None compared with placebo17

Polycarbophil (Fibercon) tablets

1,250 mg, one to four times per day

12 to 72 hours

None recorded18

Psyllium (Metamucil) powder

1 tsp or 1 packet one to three times per day

12 to 24 hours

Bloating, abdominal distension in 4% to 18%16,17

Osmotic laxatives

Lactulose solution

15 to 30 mL per day

24 to 48 hours

Bloating and cramping; nausea in up to 20%19

Magnesium citrate solution

150 to 300 mL, single dose or short-term daily dose

30 minutes to 6 hours

Increase in magnesium, causing lethargy, hypotension, respiratory depression20

Magnesium hydroxide suspension

30 to 60 mL per day

30 minutes to 6 hours

Increase in magnesium, causing lethargy, hypotension, respiratory depression20

Polyethylene glycol (Miralax) powder

17 g per day

24 to 48 hours

Minimal adverse effects of cramping and gas18

Sorbitol solution

2 to 3 tbsp, single dose or short-term daily dose

24 to 48 hours

Bloating, cramping, and nausea19

Stool softeners

Docusate sodium (Colace) capsules

100 mg twice per day

24 to 48 hours

None reported16

Stimulant laxatives

Bisacodyl (Dulcolax) tablets

5 to 15 mg per day

6 to 10 hours

Diarrhea and abdominal pain in 56% in week 1 and 5% in week 421

Senna tablets

15 mg per day

6 to 12 hours

Abdominal pain in up to 12%16

Chloride channel activators

Lubiprostone (Amitiza)† capsules

24 mcg twice per day

Within 24 hours

Nausea in 18%22

Peripherally acting mu-opioid antagonists

Methylnaltrexone (Relistor)‡ solution

Weight-based subcutaneous injection, once or twice per day

30 to 60 minutes

Diarrhea in 8%

Abdominal pain in 13%23

Other

Linaclotide (Linzess)† capsules

145 mcg per day

Diarrhea in 16%, which led to treatment cessation in 4%24


*—All formulations are oral, unless specified.

†—Estimated retail price for one month's treatment is $300, based on information obtained at http://www.goodrx.com (accessed May 15, 2015).

‡—Estimated retail price for one month's treatment is $1,200, based on information obtained at http://www.goodrx.com (accessed June 10, 2015).

Information from references 16 through 24.

Table 1.

Medications for the Treatment of Constipation

AgentTypical dosage*Time of onsetAdverse effects

Bulking agents

Methylcellulose powder

19 g per day

12 to 72 hours

None compared with placebo17

Polycarbophil (Fibercon) tablets

1,250 mg, one to four times per day

12 to 72 hours

None recorded18

Psyllium (Metamucil) powder

1 tsp or 1 packet one to three times per day

12 to 24 hours

Bloating, abdominal distension in 4% to 18%16,17

Osmotic laxatives

Lactulose solution

15 to 30 mL per day

24 to 48 hours

Bloating and cramping; nausea in up to 20%19

Magnesium citrate solution

150 to 300 mL, single dose or short-term daily dose

30 minutes to 6 hours

Increase in magnesium, causing lethargy, hypotension, respiratory depression20

Magnesium hydroxide suspension

30 to 60 mL per day

30 minutes to 6 hours

Increase in magnesium, causing lethargy, hypotension, respiratory depression20

Polyethylene glycol (Miralax) powder

17 g per day

24 to 48 hours

Minimal adverse effects of cramping and gas18

Sorbitol solution

2 to 3 tbsp, single dose or short-term daily dose

24 to 48 hours

Bloating, cramping, and nausea19

Stool softeners

Docusate sodium (Colace) capsules

100 mg twice per day

24 to 48 hours

None reported16

Stimulant laxatives

Bisacodyl (Dulcolax) tablets

5 to 15 mg per day

6 to 10 hours

Diarrhea and abdominal pain in 56% in week 1 and 5% in week 421

Senna tablets

15 mg per day

6 to 12 hours

Abdominal pain in up to 12%16

Chloride channel activators

Lubiprostone (Amitiza)† capsules

24 mcg twice per day

Within 24 hours

Nausea in 18%22

Peripherally acting mu-opioid antagonists

Methylnaltrexone (Relistor)‡ solution

Weight-based subcutaneous injection, once or twice per day

30 to 60 minutes

Diarrhea in 8%

Abdominal pain in 13%23

Other

Linaclotide (Linzess)† capsules

145 mcg per day

Diarrhea in 16%, which led to treatment cessation in 4%24


*—All formulations are oral, unless specified.

†—Estimated retail price for one month's treatment is $300, based on information obtained at http://www.goodrx.com (accessed May 15, 2015).

‡—Estimated retail price for one month's treatment is $1,200, based on information obtained at http://www.goodrx.com (accessed June 10, 2015).

Information from references 16 through 24.

View/Print Figure

Management of Chronic Constipation in Older Adults

Figure 1.

Suggested approach to management of chronic constipation in older adults.

Management of Chronic Constipation in Older Adults


Figure 1.

Suggested approach to management of chronic constipation in older adults.

ENEMAS AND SUPPOSITORIES

Enemas and suppositories can be useful for fecal impaction or in patients who cannot tolerate oral preparations. Phosphate enemas should be avoided in older adults because of the high risk of electrolyte disturbances, which are sometimes fatal.25 Mineral oil enemas are a safer alternative to phosphate enemas, with local adverse effects of perianal irritation or soreness. Plain warm water enemas are safe and preferable to soapsuds enemas, which may cause rectal mucosa damage.2 Glycerin suppositories are safe alternatives to enemas and have been shown to improve rectal emptying in patients with chronic constipation.26

BULKING AGENTS

Bulking agents may be soluble, such as psyllium (Metamucil), or insoluble, such as bran, methylcellulose (Citrucel), and polycarbophil (Fibercon). These agents absorb water into the intestine to soften the stool and increase bulk. Bran and psyllium improve stool frequency in older patients,18 but there is more evidence for the effectiveness of psyllium than bran in persons of all ages.17 A few small studies in older adults demonstrated equivalent effectiveness of methylcellulose and polycarbophil to psyllium.16 Adverse effects such as bloating, abdominal distention, and gas are more common with psyllium.27 Bulk laxatives should be avoided if fecal impaction is present.

OSMOTIC LAXATIVES

Osmotic laxatives are not absorbable. These laxatives draw water into the intestinal lumen. Lactulose and sorbitol are hyperosmolar sugar alcohols that increase frequency of defecation and reduce straining. They are metabolized by colonic bacteria and then absorbed by colonic mucosa. An RCT of 30 men 65 to 86 years of age showed that sorbitol and lactulose were equally effective in treating constipation.19 Another RCT of nursing home residents with an average age of 85 years found that lactulose was more effective than placebo.28 Lactulose may cause diarrhea in patients who are lactose intolerant.

PEG is an iso-osmotic agent that has been consistently effective in the treatment of constipation.18 A meta-analysis of PEG vs. lactulose for the treatment of chronic constipation in adults up to 75 years of age showed that PEG is more effective and led to fewer adverse effects than lactulose.29 A small RCT comparing PEG with ispaghula husk (psyllium) showed that PEG was more effective, with a more rapid onset of action.30

The effectiveness and safety of magnesium salts, such as magnesium hydroxide and magnesium citrate, have not been well studied in older adults. Magnesium toxicity is a concern with long-term use of these agents; it can cause ileus and worsen constipation. Magnesium salts should be avoided in patients with renal failure. Because of the limited data and potential harm, long-term use of magnesium salts is not recommended.

STOOL SOFTENERS

Three RCTs involving older patients showed a benefit of docusate sodium (Colace) over placebo in the treatment of constipation.16

STIMULANT LAXATIVES

Senna and bisacodyl (Dulcolax) promote intestinal motility and increase fluid secretion into the bowel. One RCT found bisacodyl to be more effective than placebo for chronic constipation; however, the average age of study participants was 55 years.21 Because of the possible adverse effects of long-term use in older persons, stimulant laxatives should be used only after fiber and osmotic laxatives have been tried. Long-term use of stimulant laxatives containing anthraquinone, such as senna, causes melanosis coli, which is a reversible histologic finding of brown pigmentation in the colonic mucosa.

OTHER AGENTS

Lubiprostone (Amitiza), a chloride channel activator that moves water into the intestinal lumen, is approved by the U.S. Food and Drug Administration for long-term treatment of chronic constipation in adults. It is effective and moderately well tolerated in older adults.16 A subgroup analysis of 163 patients older than 65 years found that nausea was the most common adverse effect, occurring in 18% of patients.22 In one study of patients with constipation after orthopedic surgery, lubiprostone was as effective as senna.31 Lubiprostone may be reserved for constipation that does not respond to less expensive treatment options.

Linaclotide (Linzess) increases intestinal fluid secretion and motility. It is approved by the U.S. Food and Drug Administration for chronic constipation and irritable bowel syndrome. Studies with patients up to 86 years of age showed increased frequency of bowel movements and decreased abdominal pain. Diarrhea is the most common adverse effect and led to cessation of treatment in 4% of patients.24

Probiotics. A systematic review of five RCTs found that probiotics did not improve constipation in adults.32

Peripherally Acting mu-Opioid Antagonists. These agents include methylnaltrexone (Relistor), alvimopan (Entereg), and naloxegol (Movantik), which decrease the gastrointestinal effects of opioids without reducing centrally mediated analgesia, and naloxone, which is also effective for constipation but can decrease analgesia. Up to 40% of patients taking opioids are constipated; of these, only 46% have an acceptable response to laxatives more than 50% of the time.33 A systematic review of studies with patients up to 78 years of age who had malignant or nonmalignant pain found that methylnaltrexone, naloxone, and alvimopan were more effective than placebo for chronic opioid-induced constipation.23 Methylnaltrexone is administered subcutaneously and is effective for opioid-induced constipation in palliative care patients with symptoms resistant to other laxatives.34 Methylnaltrexone should not be used in patients with intestinal obstruction and should be used with caution in patients with intestinal malignancy. Alvimopan, approved for short-term treatment of postoperative ileus, is available only through a restricted prescribing program because of increased risk of myocardial infarction. Naloxegol is administered orally and is approved for opioid-induced constipation in patients who do not have cancer. Peripherally acting mu-opioid antagonists are expensive, and should be used only when other options are ineffective.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Defense, the U.S. Army Medical Corps, or the U.S. Army at large.

Data Sources: A PubMed search was completed in Clinical Queries using the key terms constipation and elderly. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were the Cochrane database, Database of Abstracts of Reviews of Effects, TRIP database, the National Guideline Clearinghouse database, and UpToDate. Search dates: August 2014 and June 2, 2015.

The Authors

show all author info

ANNE MOUNSEY, MD, is a professor of clinical medicine at the University of North Carolina, Chapel Hill....

MEGHAN RALEIGH, MD, is a sports medicine fellow at the Uniformed Services University of the Health Sciences in Bethesda, Md. At the time the article was submitted, Dr. Raleigh was a faculty development fellow at the University of North Carolina, Chapel Hill.

ANTHONY WILSON, MD, is an assistant professor of family medicine at the University of Tennessee Medical Center in Knoxville, Tenn. At the time the article was submitted, Dr. Wilson was a faculty development fellow at the University of North Carolina, Chapel Hill.

Address correspondence to Anne Mounsey, MD, University of North Carolina, 590 Manning Dr., Chapel Hill, NC 27514 (e-mail: anne_mounsey@med.unc.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–238....

2. Bouras EP, Tangalos EG. Chronic constipation in the elderly. Gastroenterol Clin North Am. 2009;38(3):463–480.

3. Morley JE. Constipation and irritable bowel syndrome in the elderly. Clin Geriatr Med. 2007;23(4):823–832, vi–vii.

4. Gallagher P, O'Mahony D. Constipation in old age. Best Pract Res Clin Gastroenterol. 2009;23(6):875–887.

5. Ghoshal UC. Review of pathogenesis and management of constipation. Trop Gastroenterol. 2007;28(3):91–95.

6. Pasanen ME. Evaluation and treatment of colonic symptoms. Med Clin North Am. 2014;98(3):529–547.

7. Spinzi G, Amato A, Imperiali G, et al. Constipation in the elderly: management strategies. Drugs Aging. 2009;26(6):469–474.

8. Chin A, Paw MJ, van Poppel MN, van Mechelen W. Effects of resistance and functional-skills training on habitual activity and constipation among older adults living in long-term care facilities: a randomized controlled trial. BMC Geriatr. 2006;6:9.

9. Simmons SF, Schnelle JF. Effects of an exercise and scheduled-toileting intervention on appetite and constipation in nursing home residents. J Nutr Health Aging. 2004;8(2):116–121.

10. Meshkinpour H, Selod S, Movahedi H, Nami N, James N, Wilson A. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998;43(11):2379–2383.

11. Nour-Eldein H, Salama HM, Abdulmajeed AA, Heissam KS. The effect of lifestyle modification on severity of constipation and quality of life of elders in nursing homes at Ismailia city, Egypt. J Family Community Med. 2014;21(2):100–106.

12. Anti M, Pignataro G, Armuzzi A, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology. 1998;45(21):727–732.

13. U.S. Department of Health and Human Services; U.S. Department of Agriculture; U.S. Dietary Guidelines Advisory Committee. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: U.S. Government Printing Office; 2010.

14. Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database Syst Rev. 2014;(3):CD008486.

15. Ba-Bai-Ke-Re MM, Wen NR, Hu YL, et al. Biofeedback-guided pelvic floor exercise therapy for obstructive defecation: an effective alternative. World J Gastroenterol. 2014;20(27):9162–9169.

16. Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother. 2010;8(6):514–550.

17. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33(8):895–901.

18. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100(4):936–971.

19. Lederle FA, Busch DL, Mattox KM, West MJ, Aske DM. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am J Med. 1990;89(5):597–601.

20. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001;44(8):1201–1209.

21. Kienzle-Horn S, et al. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2006;23(10):1479–1488.

22. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41(4):345–351.

23. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(10):1566–1574.

24. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527–536.

25. Mendoza J, et al. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther. 2007;26(1):9–20.

26. Chassagne P, Jego A, Gloc P, et al. Does treatment of constipation improve faecal incontinence in institutionalized elderly patients? Age Ageing. 2000;29(2):159–164.

27. Gallagher PF, O'Mahony D, Quigley EM. Management of chronic constipation in the elderly. Drugs Aging. 2008;25(10):807–821.

28. Sanders JF. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriatr Soc. 1978;26(5):236–239.

29. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.

30. Wang HJ, Liang XM, Yu ZL, Zhou LY, Lin SR, Geraint M. A randomised, controlled comparison of low-dose polyethylene glycol 3350 plus electrolytes with ispaghula husk in the treatment of adults with chronic functional constipation. Clin Drug Investig. 2004;24(10):569–576.

31. Marciniak CM, et al. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial. World J Gastroenterol. 2014;20(43):16323–16333.

32. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 2010;16(1):69–75.

33. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S–18S.

34. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;(1):CD003448.



 

Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article